Market capitalization | $76.27m |
Enterprise Value | $-107.60m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 1.16 |
P/B ratio (TTM) P/B ratio | 0.36 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-128.44m |
Free Cash Flow (TTM) Free Cash Flow | $-92.84m |
Cash position | $202.07m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
8 Analysts have issued a Adicet Bio Inc forecast:
8 Analysts have issued a Adicet Bio Inc forecast:
Sep '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -6.53 -6.53 |
21%
21%
|
|
EBITDA | -122 -122 |
2%
2%
|
EBIT (Operating Income) EBIT | -128 -128 |
3%
3%
|
Net Profit | -118 -118 |
18%
18%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
resTORbio, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the development and commercialization of medicines for aging-related diseases and conditions. It offers an immunotherapy under the TORC1 program. The company was founded by Chen Schor and Joan Mannick on July 5, 2016 and is headquartered in Boston, MA.
Head office | United States |
CEO | Chen Schor |
Employees | 143 |
Founded | 2014 |
Website | www.adicetbio.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.